Timothy J. Ley, Washington University School of Medicine (image) Washington University School of Medicine Share Print E-Mail Caption Eight in 10 patients with acute myeloid leukemia relapse after remission, and for most of them there's no reliable way to predict relapse. But new research by Timothy J. Ley, MD, and colleagues at Washington University in St. Louis suggests that performing genetic profiling while a patient is in remission can help physicians assess response to treatment and determine whether aggressive, follow-up treatment is necessary. Credit Mark Katzman Usage Restrictions Credit to Mark Katzman Share Print E-Mail Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.